Tags

Type your tag names separated by a space and hit enter

Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
Clin Cancer Res. 2007 Aug 01; 13(15 Pt 1):4422-8.CC

Abstract

PURPOSE

The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging. However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases. Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions. The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125.

EXPERIMENTAL DESIGN

We here validate the performance of hK11 on an independent data set and further characterize its behavior in multiple types of controls. We also investigate its behavior when combined with CA 125 to form a composite marker. hK11 had not previously been evaluated on these serum samples. CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability.

RESULTS

hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.

CONCLUSION

We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.

Authors+Show Affiliations

Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study

Language

eng

PubMed ID

17671125

Citation

McIntosh, Martin W., et al. "Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 13, no. 15 Pt 1, 2007, pp. 4422-8.
McIntosh MW, Liu Y, Drescher C, et al. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res. 2007;13(15 Pt 1):4422-8.
McIntosh, M. W., Liu, Y., Drescher, C., Urban, N., & Diamandis, E. P. (2007). Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 13(15 Pt 1), 4422-8.
McIntosh MW, et al. Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8. PubMed PMID: 17671125.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. AU - McIntosh,Martin W, AU - Liu,Yan, AU - Drescher,Charles, AU - Urban,Nicole, AU - Diamandis,Eleftherios P, PY - 2007/8/3/pubmed PY - 2007/10/30/medline PY - 2007/8/3/entrez SP - 4422 EP - 8 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 13 IS - 15 Pt 1 N2 - PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging. However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases. Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions. The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125. EXPERIMENTAL DESIGN: We here validate the performance of hK11 on an independent data set and further characterize its behavior in multiple types of controls. We also investigate its behavior when combined with CA 125 to form a composite marker. hK11 had not previously been evaluated on these serum samples. CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability. RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125. CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/17671125/Validation_and_characterization_of_human_kallikrein_11_as_a_serum_marker_for_diagnosis_of_ovarian_carcinoma_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=17671125 DB - PRIME DP - Unbound Medicine ER -